Goncalves L, Guedes H, Fortuna A, Lemos T, Gramaca J, Mourao N
Cancers (Basel). 2025; 17(5).
PMID: 40075745
PMC: 11898965.
DOI: 10.3390/cancers17050898.
Schlack K, Machtens S, Kubin T, Ruhnke M, Schulte C, Eisen A
J Cancer Res Clin Oncol. 2025; 151(3):100.
PMID: 40042678
PMC: 11882626.
DOI: 10.1007/s00432-025-06131-y.
Fiala O, Buti S, Fujita K, de Liano A, Fukuokaya W, Kimura T
Clin Exp Metastasis. 2025; 42(2):18.
PMID: 39976819
PMC: 11842414.
DOI: 10.1007/s10585-025-10335-4.
Pelaez I, Lazaro-Quintela M, Perez-Fentes D, Esteban-Gonzalez E, Gallardo E, Alvarez-Fernandez C
Clin Transl Oncol. 2025; .
PMID: 39961959
DOI: 10.1007/s12094-025-03850-z.
ODwyer R, Junker S, Szulkin R, Kienzle S, Kearney M, Sridhar S
Cancers (Basel). 2025; 17(3).
PMID: 39941876
PMC: 11816825.
DOI: 10.3390/cancers17030509.
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.
Meirson T, Ofer J, Zimhony-Nissim N, Bareket-Samish A, Markel G, Neiman V
JAMA Netw Open. 2025; 8(1):e2455630.
PMID: 39841472
PMC: 11755191.
DOI: 10.1001/jamanetworkopen.2024.55630.
Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain.
Hasaligil A, Munro V, Strunz-McKendry T, Wang-Silvanto J, Milloy N, Unsworth M
Future Oncol. 2025; 21(5):569-578.
PMID: 39789976
PMC: 11845109.
DOI: 10.1080/14796694.2024.2445498.
Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives.
Testi I, Giudice G, Salfi G, Pedrani M, Merler S, Turco F
Explor Target Antitumor Ther. 2025; 5(6):1326-1364.
PMID: 39764422
PMC: 11702265.
DOI: 10.37349/etat.2024.00279.
Combining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors.
Cheng L, Su P, Kuo M, Lin C, Luo H, Chou C
Ther Adv Med Oncol. 2024; 16:17588359241305091.
PMID: 39687055
PMC: 11648016.
DOI: 10.1177/17588359241305091.
The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer.
Vlachou E, Johnson B, Hoffman-Censits J
Clin Med Insights Oncol. 2024; 18:11795549241290787.
PMID: 39686979
PMC: 11648052.
DOI: 10.1177/11795549241290787.
Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives.
Kwon W, Lee M
Cancers (Basel). 2024; 16(23).
PMID: 39682263
PMC: 11640162.
DOI: 10.3390/cancers16234078.
Use of 3' Rapid Amplification of cDNA Ends (3' RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas.
Mitiushkina N, Tiurin V, Anuskina A, Bordovskaya N, Nalivalkina E, Terina D
Int J Mol Sci. 2024; 25(22).
PMID: 39596194
PMC: 11594887.
DOI: 10.3390/ijms252212126.
Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.
Li S, Shi Y, Dong H, Guo H, Xie Y, Sun Z
Cancer Med. 2024; 13(21):e70368.
PMID: 39530574
PMC: 11555717.
DOI: 10.1002/cam4.70368.
Co‑occurrence of clear cell renal cell carcinoma and bladder urothelial carcinoma: A case report and literature review.
Wu S, Zuo Y, Ye M, Wang K, Wang X, Yang X
Oncol Lett. 2024; 29(1):21.
PMID: 39492932
PMC: 11526436.
DOI: 10.3892/ol.2024.14768.
Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.
Klumper N, Cox A, Sjodahl G, Roghmann F, Bolenz C, Hartmann A
Nat Rev Urol. 2024; .
PMID: 39472646
DOI: 10.1038/s41585-024-00951-2.
Oligometastatic Urothelial Cancer and Stereotactic Body Radiotherapy: A Systematic Review and an Updated Insight of Current Evidence and Future Directions.
Angrisani A, Bosetti D, Vogl U, Castronovo F, Zilli T
Cancers (Basel). 2024; 16(18).
PMID: 39335172
PMC: 11430162.
DOI: 10.3390/cancers16183201.
Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States.
Moon H, Kearney M, Mahmoudpour S, Ike C, Morris V, Rava A
Curr Oncol. 2024; 31(9):5662-5676.
PMID: 39330048
PMC: 11431044.
DOI: 10.3390/curroncol31090420.
Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review.
Dimitrov G, Mangaldzhiev R, Slavov C, Popov E
Cancers (Basel). 2024; 16(17).
PMID: 39272913
PMC: 11394076.
DOI: 10.3390/cancers16173056.
Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma.
van Sanden S, Youssef A, Baculea S, Stubbs K, Triantos S, Yuan Z
J Health Econ Outcomes Res. 2024; 11(2):49-57.
PMID: 39267886
PMC: 11392482.
DOI: 10.36469/001c.120954.
Urothelial cancer: state of art in Ukraine and improvement pathways.
Pikul M, Gordiichuk P, Stakhovsky E
Ann Med Surg (Lond). 2024; 86(9):5137-5144.
PMID: 39238972
PMC: 11374189.
DOI: 10.1097/MS9.0000000000002424.
